NCT03913039

Brief Summary

Prostate biopsy is typically performed via either the transrectal or transperineal approach. This study is a case-control study being done to determine if a novel prostate biopsy protocol incorporating a transperineal approach, rectal swab to detect resistant bacteria and broad antibiotic prophylaxis will reduce infectious complications and hospital readmission compared to current biopsy practices.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
157

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 10, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 12, 2019

Completed
19 days until next milestone

Study Start

First participant enrolled

May 1, 2019

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

February 10, 2022

Status Verified

February 1, 2022

Enrollment Period

2.5 years

First QC Date

April 10, 2019

Last Update Submit

February 8, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of clinically significant post-biopsy complications

    1\. Rate of any clinically significant post-biopsy complications including infectious complications and hospital readmissions within 30 days.

    30 Days

Secondary Outcomes (1)

  • 1. Number of individual complications within 30 days

    30 Days

Study Arms (2)

transperineal protocol

1. Transperineal biopsy approach with avoidance of rectal flora 2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated 3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria 4. Multi-antibiotic prophylaxis 5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.

Procedure: Transperineal biopsy Protocol

Traditional biopsy

1. Transrectal approach 2. Standard 12-core template 3. Surgeon-specific antibiotic prophylaxis 4. Urine culture, prostate tissue culture and FQR rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.

Interventions

1. Transperineal biopsy approach with avoidance of rectal flora 2. MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated 3. Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria 4. Multi-antibiotic prophylaxis 5. Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns.

transperineal protocol

Eligibility Criteria

Age18 Years - 120 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsAssessment of Prostate Cancer treatment - - only males qualify.
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Males with clinical indication for a prostate biopsy.

You may qualify if:

  • Male patients greater than 18 years of age
  • Indication for prostate biopsy

You may not qualify if:

  • Female patients
  • Male patients under 18 years of age
  • No indication for prostate biopsy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maimonides Medical Center

Brooklyn, New York, 11219, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 10, 2019

First Posted

April 12, 2019

Study Start

May 1, 2019

Primary Completion

October 31, 2021

Study Completion

December 31, 2021

Last Updated

February 10, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

Locations